These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 38918965)

  • 1. Impact of Body Composition on Clinical Outcomes in Patients with Esophageal Squamous Cell Carcinoma Receiving Neoadjuvant Immunotherapy Plus Chemotherapy.
    Zhao Y; Xia M; Dang Y; Li Y; Zhao X; Kang N; Zuo J; Zhang R
    Ann Ital Chir; 2024; 95(3):284-293. PubMed ID: 38918965
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and Feasibility of Esophagectomy Following Combined Immunotherapy and Chemotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma: A Propensity Score Matching Analysis.
    Hong ZN; Gao L; Weng K; Huang Z; Han W; Kang M
    Front Immunol; 2022; 13():836338. PubMed ID: 35300335
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Survival outcomes of neoadjuvant immunochemotherapy versus chemotherapy for locally advanced esophageal squamous cell carcinoma.
    Lv H; Zhang F; Huang C; Xu S; Li J; Sun B; Gai C; Liu Z; Wang M; Li Z; Tian Z
    J Cancer Res Clin Oncol; 2024 May; 150(5):260. PubMed ID: 38760614
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of pathologic response and survival outcomes between neoadjuvant chemoradiotherapy (nCRT) and neoadjuvant immunochemotherapy (nICT) in patients with locally advanced esophageal squamous cell carcinoma: a propensity score-matched analysis.
    Wang Y; Ma K; Zhang H; Wu L; Liu L; Zhou Y; Peng L; Wang Q; Zhuang X
    BMC Cancer; 2024 Oct; 24(1):1228. PubMed ID: 39369225
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pathologic responses and surgical outcomes after neoadjuvant immunochemotherapy versus neoadjuvant chemoradiotherapy in patients with locally advanced esophageal squamous cell carcinoma.
    Xu L; Wei XF; Li CJ; Yang ZY; Yu YK; Li HM; Xie HN; Yang YF; Jing WW; Wang Z; Kang XZ; Zhang RX; Qin JJ; Xue LY; Bi N; Chen XK; Li Y
    Front Immunol; 2022; 13():1052542. PubMed ID: 36466925
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical significance of geriatric nutritional risk index in esophageal squamous cell carcinoma receiving neoadjuvant immunotherapy.
    Feng J; Wang L; Yang X; Chen Q; Cheng X
    Eur J Surg Oncol; 2024 Jun; 50(6):108323. PubMed ID: 38603867
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Additional neoadjuvant immunotherapy does not increase the risk of anastomotic leakage after esophagectomy for esophageal squamous cell carcinoma: a multicenter retrospective cohort study.
    Hong Z; Xu J; Chen Z; Xu H; Huang Z; Weng K; Cai J; Ke S; Chen S; Xie J; Duan H; Kang M
    Int J Surg; 2023 Aug; 109(8):2168-2178. PubMed ID: 37318861
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Comparison of Clinicopathologic Outcomes and Patterns of Lymphatic Spread Across Neoadjuvant Chemotherapy, Neoadjuvant Chemoradiotherapy, and Neoadjuvant Immunochemotherapy in Locally Advanced Esophageal Squamous Cell Carcinoma.
    Tian Y; Shi Z; Wang C; Ke S; Qiu H; Zhao W; Wu Y; Chen J; Zhang Y; Chen Y
    Ann Surg Oncol; 2024 Feb; 31(2):860-871. PubMed ID: 37947979
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A propensity score-matched analysis of neoadjuvant chemoimmunotherapy versus surgery alone for locally advanced esophageal squamous cell carcinoma.
    Wang K; Liang Y; Huang J; Xie X; Wu D; Chen B; Wang K; Shen Z; Li Y; Wang W; Hu X; Wang M
    J Surg Oncol; 2023 Aug; 128(2):207-217. PubMed ID: 37036218
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dynamic radiological features predict pathological response after neoadjuvant immunochemotherapy in esophageal squamous cell carcinoma.
    Ruan Y; Ma Y; Ma M; Liu C; Su D; Guan X; Yang R; Wang H; Li T; Zhou Y; Ma J; Zhang Y
    J Transl Med; 2024 May; 22(1):471. PubMed ID: 38762454
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Perioperative outcomes of neoadjuvant immunotherapy plus chemotherapy and neoadjuvant chemoradiotherapy in the treatment of locally advanced esophageal squamous cell carcinoma: a retrospective comparative cohort study.
    Zhang H; Zhang Z; Yang L; Wu B; Chen Y; He H; Li C; Lin W; Lin J
    J Thorac Dis; 2023 Mar; 15(3):1279-1288. PubMed ID: 37065590
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of the interval between neoadjuvant immunotherapy and surgery on prognosis in esophageal squamous cell carcinoma (ESCC): a real-world study.
    Yang G; Hong Y; Zhang X; Zeng C; Tan L; Zhang X
    Cancer Immunol Immunother; 2024 Aug; 73(10):202. PubMed ID: 39105817
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Morbidity and Mortality of Patients Who Underwent Minimally Invasive Esophagectomy After Neoadjuvant Chemoradiotherapy vs Neoadjuvant Chemotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma: A Randomized Clinical Trial.
    Wang H; Tang H; Fang Y; Tan L; Yin J; Shen Y; Zeng Z; Zhu J; Hou Y; Du M; Jiao J; Jiang H; Gong L; Li Z; Liu J; Xie D; Li W; Lian C; Zhao Q; Chen C; Zheng B; Liao Y; Li K; Li H; Wu H; Dai L; Chen KN
    JAMA Surg; 2021 May; 156(5):444-451. PubMed ID: 33729467
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Body composition parameters predict pathological response and outcomes in locally advanced gastric cancer after neoadjuvant treatment: A multicenter, international study.
    Lin JX; Tang YH; Zhou WX; Desiderio J; Parisi A; Xie JW; Wang JB; Cianchi F; Antonuzzo L; Borghi F; Lu J; Chen QY; Cao LL; Lin M; Tu RH; Staderini F; Marano A; Peluso C; Li P; Zheng CH; Ma YB; Huang CM
    Clin Nutr; 2021 Aug; 40(8):4980-4987. PubMed ID: 34364237
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel immune-nutritional score predicts response to neoadjuvant immunochemotherapy after minimally invasive esophagectomy for esophageal squamous cell carcinoma.
    Feng J; Wang L; Yang X; Chen Q; Cheng X
    Front Immunol; 2023; 14():1217967. PubMed ID: 37954582
    [TBL] [Abstract][Full Text] [Related]  

  • 16.
    Wang S; Di S; Lu J; Xie S; Yu Z; Liang Y; Gong T
    Thorac Cancer; 2023 Aug; 14(24):2338-2349. PubMed ID: 37424279
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of SPARC and TUBB3 as predictors for prognosis in esophageal squamous cell carcinoma receiving nab-paclitaxel plus cisplatin neoadjuvant chemotherapy: a prospective study.
    Gong L; Mao W; Chen Q; Jiang Y; Fan Y
    Cancer Chemother Pharmacol; 2019 Apr; 83(4):639-647. PubMed ID: 30643929
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of Neoadjuvant Immunotherapy Combined with Chemotherapy on Pulmonary Function and Postoperative Pulmonary Complications in Esophageal Cancer: A Retrospective Study.
    Gao Y; Zhang H; Qiu Y; Bian X; Wang X; Li Y
    Curr Cancer Drug Targets; 2024; 24(10):1061-1070. PubMed ID: 38310460
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comprehensive nutritional index predicts clinical outcomes for esophageal squamous cell carcinoma receiving neoadjuvant immunotherapy combined with chemotherapy.
    Feng J; Wang L; Yang X; Chen Q; Cheng X
    Int Immunopharmacol; 2023 Aug; 121():110459. PubMed ID: 37307758
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The efficacy and safety of neoadjuvant immunotherapy in resectable locally advanced esophageal squamous cell carcinoma: A systematic review and meta-analysis.
    He W; Wang C; Li C; Nie X; Li H; Li J; Zhao N; Chen H; Miao X; Han Y; Peng L; Leng X
    Front Immunol; 2023; 14():1118902. PubMed ID: 36875107
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.